Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | VNN1 | O95497 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | MAOA | P21397 | 2/20 | 0.48 |
| ▸ | MAOB | P27338 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.47 |
| ▸ | PGK1 | P00558 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.46 |
| ▸ | ALPL | P05186 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17714697 | 0.85 | KMT2A (0.53) | KMT2AVNN1MEN1RAB9AMAPT | |
| SCHEMBL15722555 | 0.82 | MAOA (0.51) | VNN1RAB9AMAPTKDM4EHPGD | |
| SCHEMBL15722546 | 0.80 | KMT2A (0.47) | KMT2AVNN1MEN1RAB9AMAPT | |
| SCHEMBL22163151 | 0.79 | HTR1A (0.69) | KMT2AVNN1MEN1RAB9AMAPT | |
| SCHEMBL9540087 | 0.79 | CTSB (0.58) | KMT2AVNN1MEN1RAB9AMAPT | |
| SCHEMBL6814420 | 0.79 | NCF1 (0.54) | KMT2AMEN1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL15722545 | 0.78 | MAOA (0.62) | KMT2AMEN1RAB9AMAPTKDM4E | |
| SCHEMBL10498883 | 0.78 | MAOA (0.60) | KMT2AMEN1RAB9AMAPTKDM4E | |
| SCHEMBL11625224 | 0.77 | NPC1 (0.71) | KMT2AVNN1MEN1RAB9AMAPT | |
| SCHEMBL21855430 | 0.76 | KMT2A (0.69) | KMT2AMEN1RAB9AMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11077107-B2 | Triazolopyrazine | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2021-08-03 | — | — | US | disclosed |
| US-20190240219-A1 | TRIAZOLOPYRAZINE | BOEHRINGER INGELHEIM INT (DE) | 2019-08-08 | — | — | US | disclosed |
| US-10328074-B2 | Substituted [1,2,4]triazolo[4,3-a]pyrazines as BRD4 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-06-25 | — | — | US | disclosed |
| EP-3022196-B1 | NOVEL BENZIMIDAZOLIUM COMPOUNDS | BOEHRINGER INGELHEIM INT (DE) | 2017-09-06 | — | — | EP | disclosed |
| EP-2925761-B1 | TRIAZOLOPYRAZINES AS BRD4 INHIBITORS FOR USE IN THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INT (DE) | 2017-07-05 | — | — | EP | disclosed |
| US-20160129001-A1 | SUBSTITUTED [1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS BRD4 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2016-05-12 | — | — | US | disclosed |
| US-20160129001-A1 | SUBSTITUTED [1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS BRD4 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2016-05-12 | — | — | US | disclosed |
| US-9328131-B2 | Benzimidazolium compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-05-03 | — | — | US | disclosed |
| WO-2015007519-A1 | NOVEL BENZIMIDAZOLIUM COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-01-22 | — | — | WO | disclosed |
| WO-2014076237-A1 | TRIAZOLOPYRAZINE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-05-22 | — | — | WO | disclosed |
| US-20140142098-A1 | TRIAZOLOPYRAZINE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-05-22 | — | — | US | disclosed |
| US-20140142098-A1 | TRIAZOLOPYRAZINE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-05-22 | — | — | US | disclosed |
| EP-0151826-A1 | 4-[(Bicyclic heterocyclyl)-methyl and -hetero]-piperidines | JANSSEN PHARMACEUTICA N.V. (BE) | 1985-08-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190240219-A1 | TRIAZOLOPYRAZINE | MKI67, CCNI, CCNT2 | KMT2A 2442/4885VNN1 4427/4885MEN1 1278/4885 |
| US-20160129001-A1 | SUBSTITUTED [1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS BRD4 INHIBITORS | BRD4, BRD3, BICRA | KMT2A 42/4885VNN1 4827/4885MEN1 1495/4885 |
| US-20140142098-A1 | TRIAZOLOPYRAZINE | MKI67, CCNI, CCNT2 | KMT2A 2442/4885VNN1 4427/4885MEN1 1278/4885 |
| US-10328074-B2 | Substituted [1,2,4]triazolo[4,3-a]pyrazines as BRD4 inhibitors | BRD4, BRD3, BICRA | KMT2A 42/4885VNN1 4827/4885MEN1 1495/4885 |
| US-11077107-B2 | Triazolopyrazine | MKI67, CCNI, CCNT2 | KMT2A 2442/4885VNN1 4427/4885MEN1 1278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.